Does Blue Cross Blue Shield of Arizona Cover Trulicity?

How BCBSAZ Formulary Placement Works for Trulicity

Blue Cross Blue Shield of Arizona maintains multiple formularies across its commercial HMO, PPO, and Medicare Advantage product lines. Trulicity (dulaglutide) appears on most of these formularies, but the tier assignment and cost-sharing structure differ by plan. Understanding your specific formulary is the first step toward predicting your out-of-pocket expense.

Commercial Plan Tiers

On standard BCBSAZ commercial plans, Trulicity typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred specialty). Tier 3 copays generally range from $50 to $75 after the deductible, while Tier 4 coinsurance can reach 25% to 40% of the drug's list price. The wholesale acquisition cost (WAC) for Trulicity 1.5 mg is approximately $1,067 for a 28-day supply, according to Eli Lilly's pricing disclosures filed with the FDA [1]. That means a 30% coinsurance on Tier 4 could exceed $300 per month before any savings programs.

Medicare Advantage Formularies

For BCBSAZ Medicare Advantage members, Trulicity is covered under Part D prescription drug benefits. The Centers for Medicare & Medicaid Services (CMS) requires all Part D plans to cover at least two drugs per pharmacologic class [2]. Because GLP-1 receptor agonists form a distinct class, plans must include at least two options. BCBSAZ Medicare Advantage formularies typically list both Trulicity and Ozempic, though preferred status varies by plan year.

How to Check Your Specific Plan

Log into the BCBSAZ member portal or call the number on your insurance card to request your plan's formulary document. Look for dulaglutide by generic name. The formulary will show the tier, any step-therapy requirements, quantity limits, and whether prior authorization applies.

Prior Authorization Requirements

BCBSAZ requires prior authorization (PA) for Trulicity on the majority of its plans. This is standard practice among large insurers for GLP-1 receptor agonists, which the American Diabetes Association (ADA) includes in its 2024 Standards of Care as second-line agents after metformin for type 2 diabetes [3].

What the PA Process Involves

Your prescribing clinician submits documentation to BCBSAZ confirming a diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x), current HbA1c value, and prior medication trials. Most BCBSAZ PA forms require evidence that the patient has tried and either failed or is intolerant to metformin, which remains the ADA's recommended first-line pharmacotherapy [4].

Step-Therapy Protocols

Some BCBSAZ plans enforce step therapy before approving Trulicity. Step therapy means the insurer wants documentation that less expensive medications were tried first. A typical step-therapy sequence might require:

• Trial of metformin for at least 90 days at a dose of 1,500 to 2,000 mg daily
• Documented HbA1c remaining above 7.0% (or an individualized target) despite adherence
• Clinical rationale for choosing a GLP-1 RA over a sulfonylurea or SGLT2 inhibitor

The ADA's 2024 consensus report notes that GLP-1 RAs are preferred over sulfonylureas as add-on therapy when weight management or cardiovascular risk reduction is a priority [3]. Citing this guideline in the PA submission may strengthen approval odds.

Turnaround Time and Appeals

BCBSAZ processes standard PA requests within 72 hours for non-urgent cases and within 24 hours for urgent requests. If denied, patients have the right to a formulary exception appeal. According to CMS regulations for Medicare Advantage plans, the insurer must respond to a standard appeal within 7 calendar days [5]. For commercial plans, Arizona state insurance law requires a determination within 15 business days.

Clinical Evidence Supporting Trulicity Coverage

Insurers base formulary decisions partly on clinical trial data. Trulicity has one of the broadest evidence bases among GLP-1 receptor agonists, driven primarily by the REWIND trial and the AWARD trial program.

The REWIND Cardiovascular Outcomes Trial

The REWIND trial (N=9,901) randomized adults with type 2 diabetes to dulaglutide 1.5 mg weekly or placebo over a median 5.4 years [6]. The primary composite endpoint of major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 12.0% of the dulaglutide group vs. 13.4% of the placebo group (HR 0.88, 95% CI 0.79 to 0.99, P=0.026). This result led the FDA to approve a cardiovascular risk reduction indication for Trulicity in adults with T2DM and established cardiovascular disease [7].

Glycemic Efficacy from the AWARD Program

Across the AWARD trial program, dulaglutide 1.5 mg reduced HbA1c by 0.8% to 1.6% from baseline depending on comparator and background therapy [8]. In AWARD-1 (N=978), dulaglutide 1.5 mg produced a mean HbA1c reduction of 1.51% at 26 weeks vs. 0.99% for exenatide 10 mcg twice daily [8]. Weight loss was modest, typically 1.5 to 3.0 kg over 26 to 52 weeks.

How This Evidence Affects Coverage Decisions

The Endocrine Society's 2022 clinical practice guideline on pharmacologic treatment of type 2 diabetes recommends GLP-1 RAs with proven cardiovascular benefit (including dulaglutide) for patients with atherosclerotic cardiovascular disease [9]. BCBSAZ and other payers reference these guidelines when determining formulary status. Trulicity's cardiovascular indication gives it a clinical advantage in PA approval for patients with established CVD.

Cost-Reduction Strategies for BCBSAZ Members

Even with BCBSAZ coverage, Trulicity can be expensive. Several strategies can reduce out-of-pocket spending.

Eli Lilly Trulicity Savings Card

Commercially insured patients (not Medicare, Medicaid, or Tricare beneficiaries) may qualify for the Eli Lilly Trulicity Savings Card, which can reduce copays to as little as $25 per prescription for up to 12 months [10]. The maximum benefit is typically $150 per fill. Patients can verify eligibility through their prescriber or pharmacy.

Eli Lilly Solutions Center

For patients with household income below 400% of the federal poverty level, Eli Lilly's patient assistance program (Lilly Cares) provides Trulicity at no cost. The FDA's patient assistance directory lists manufacturer programs for qualifying patients [10].

Preferred Alternative GLP-1s

If Trulicity sits on a non-preferred tier on your BCBSAZ plan, ask your provider whether a preferred-tier GLP-1 RA could work. The 2024 ADA Standards of Care do not rank individual GLP-1 RAs by preference, instead recommending the class broadly [3]. Switching to a preferred-tier option (such as Ozempic if it sits on Tier 3 while Trulicity is on Tier 4) could cut copay costs substantially without sacrificing glycemic efficacy.

Formulary Exception Requests

If your clinician believes Trulicity is medically necessary and no formulary alternative is appropriate, BCBSAZ allows a formulary exception request [5]. The prescriber must submit a letter of medical necessity documenting why the patient requires dulaglutide specifically. Reasons might include prior adverse reactions to other GLP-1 RAs, superior glycemic response to dulaglutide in prior use, or the need for cardiovascular risk reduction in a patient who cannot tolerate semaglutide.

Trulicity Dosing and What Your Prescription Should Look Like

Understanding the standard dosing helps you verify that your pharmacy claim processes correctly under your BCBSAZ plan.

Standard Dose Escalation

The FDA-approved prescribing information for Trulicity specifies an initial dose of 0.75 mg subcutaneously once weekly, with escalation to 1.5 mg weekly after at least 4 weeks if additional glycemic control is needed [7]. In 2020, the FDA approved higher doses of 3.0 mg and 4.5 mg weekly for patients requiring further HbA1c reduction [7].

Quantity Limits Under BCBSAZ

Most BCBSAZ plans authorize 4 pens per 28-day fill at the prescribed dose strength. If your provider prescribes the 4.5 mg dose, confirm that the PA covers this strength specifically, as some older PA approvals may reference only the 0.75 mg or 1.5 mg doses.

Injection Technique and Adherence

Trulicity uses a single-use, pre-filled pen with a hidden needle. The CDC's diabetes self-management education guidelines recommend rotating injection sites among the abdomen, thigh, and upper arm to reduce lipodystrophy risk [11]. Adherence to weekly GLP-1 RA injections tends to be higher than daily regimens. A real-world claims analysis published in Diabetes Care (N=51,771) found that weekly GLP-1 RA users had 12-month adherence rates (proportion of days covered ≥0.80) of 56% vs. 41% for daily users [12].

How Trulicity Compares to Other Covered GLP-1s on BCBSAZ

BCBSAZ formularies typically include several GLP-1 receptor agonists. Knowing how they compare helps guide conversations with your provider about the best option for your coverage and clinical profile.

Trulicity vs. Ozempic

The SUSTAIN 7 trial (N=1,201) compared semaglutide 0.5 mg and 1.0 mg weekly to dulaglutide 0.75 mg and 1.5 mg weekly over 40 weeks [13]. Semaglutide 1.0 mg produced a mean HbA1c reduction of 1.8% vs. 1.4% for dulaglutide 1.5 mg. Weight loss favored semaglutide: 6.5 kg vs. 3.0 kg. Both drugs carry FDA-approved cardiovascular benefit indications. On BCBSAZ formularies, Ozempic and Trulicity may sit on the same tier or different tiers depending on the plan year.

Trulicity vs. Mounjaro

Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, demonstrated superior HbA1c reduction and weight loss compared to semaglutide 1 mg in the SURPASS-2 trial (N=1,879) [14]. Tirzepatide 15 mg produced a mean HbA1c reduction of 2.3% vs. 1.9% for semaglutide 1 mg. No head-to-head trial has compared tirzepatide directly to dulaglutide. Mounjaro may require separate PA criteria on BCBSAZ plans and could sit on a higher tier.

Choosing the Right GLP-1 for Your Plan

When discussing options with your prescriber, consider three factors: formulary tier and copay on your specific BCBSAZ plan, clinical priorities (cardiovascular protection vs. Maximal weight loss vs. Oral administration), and the strength of PA approval likelihood based on your medication history. The ADA's 2024 treatment algorithm supports selecting any GLP-1 RA with cardiovascular benefit for patients with established atherosclerotic disease [3].

What to Do If BCBSAZ Denies Trulicity Coverage

A denial does not mean you cannot get Trulicity covered. Multiple pathways exist to overturn the decision.

Internal Appeal

File an internal appeal through BCBSAZ within 180 days of the denial for commercial plans. Include updated lab work (HbA1c, renal function), documentation of prior medication trials, and a letter from your prescriber referencing ADA or Endocrine Society guidelines [3][9]. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides patient-facing resources explaining why specific diabetes medications may be medically necessary [15].

External Review

If the internal appeal is denied, Arizona law allows an independent external review through the Arizona Department of Insurance. The external reviewer evaluates whether the denial was consistent with evidence-based medicine. For Medicare Advantage plans, a denied appeal can be escalated to the CMS Independent Review Entity [5].

Switching Plans During Open Enrollment

If your current BCBSAZ plan consistently places Trulicity on a high-cost tier, review alternative BCBSAZ plan options during annual open enrollment. Compare formularies side by side. A plan with a higher monthly premium but lower specialty-tier coinsurance may save money overall if you fill Trulicity every month. The CDC reports that approximately 37.3 million Americans have diabetes, and medication costs remain a top barrier to adherence [16].

Arizona-Specific Insurance Protections for Diabetes Medications

Arizona has enacted legislation affecting diabetes medication coverage that may benefit Trulicity users.

State Insulin and Diabetes Drug Mandates

Arizona's insulin copay cap law (ARS 20-826.01) limits insulin copays to $75 per 30-day supply for state-regulated plans. While this law applies specifically to insulin products and not GLP-1 RAs, it reflects a legislative trend toward diabetes medication affordability. The ADA's advocacy resources track state-level insurance mandates affecting diabetes care [17].

Surprise Billing Protections

The federal No Surprises Act and Arizona's balance billing protections (ARS 20-3102) do not directly affect pharmacy benefits but may reduce costs for diabetes-related provider visits and lab work that accompany Trulicity prescriptions. Understanding your in-network providers for endocrinology or primary care within BCBSAZ helps avoid unexpected charges.

Pharmacy Benefit Manager Transparency

Arizona's PBM transparency law (ARS 20-3352) requires pharmacy benefit managers working with Arizona-regulated insurers to disclose rebate information to plan sponsors. Because Eli Lilly offers significant rebates on Trulicity, BCBSAZ's net cost for dulaglutide may be lower than the list price, which can influence formulary placement decisions [18].